---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058254"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:18:50.763849+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows

## Summary
- Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY
- Net loss $65.2M ($0.40 per share) vs $27.2M loss YoY; includes $100M upfront for worldwide DAYBUE rights
- Full-year 2023 guidance: NUPLAZID net sales $537.5-545M; R&D $340-350M; SG&A $390-400M
- Plans to start Phase 3 for ACP-101 (Prader-Willi) and Phase 2/3 for ACP-204 (Alzheimer's psychosis) in Q4 2023
- Appoints Albert Kildani as SVP IR and Stephanie Kim as SVP Regulatory Affairs

## SEC filing metadata
- accession: 0000950170-23-058254
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/acad-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058254
- JSON: https://secwatch.observer/filing/0000950170-23-058254.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058254.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $211.7 million, net income $65.2 million, EPS $0.40 per common share. Guidance initiated.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $211.7 million
  - Net income: $65.2 million
  - EPS: $0.40 per common share
  - Guidance: initiated
  - Result: reported results
  source text: Total revenues, comprised of net product sales from NUPLAZID and DAYBUE were $211.7 million for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported the nine months ended September 30, 2023 results: revenue $495.4 million, net income $107.1 million, EPS $0.65 per common share. Guidance initiated.
  - Period: the nine months ended September 30, 2023
  - Revenue: $495.4 million
  - Net income: $107.1 million
  - EPS: $0.65 per common share
  - Guidance: initiated
  - Result: reported results
  source text: and were $495.4 million for the nine months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.